- Fresenius SE’s EBIT (Earnings Before Interest and Taxes) before special items for Q2 was €660 million, exceeding the estimated €634.1 million.
- Fresenius Kabi’s EBIT before special items reached €334 million, beating the estimate of €308.2 million.
- Fresenius Helios’ EBIT before special items was €357 million, higher than the estimated €343.3 million.
- Overall sales amounted to €5.41 billion, slightly below the estimate of €5.47 billion.
- Fresenius Kabi’s sales were €2.10 billion, just under the estimate of €2.12 billion.
- Fresenius Helios’ sales totaled €3.23 billion, surpassing the estimate of €3.18 billion.
- Net income excluding special items was €457 million, well above the estimated €412.2 million.
- Fresenius maintains its forecast for organic revenue growth of 4% to 7% for the year.
- The company is optimistic about achieving the upper half of its constant currency EBIT growth target (6% to 10%) for the fiscal year 2024.
- CEO Michael Sen stated that the firm is ahead of schedule in its efforts to reduce debt and cut costs.
A look at Fresenius & KGaA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Fresenius SE & Co KGaA, a global healthcare group, is positioned favorably for long-term growth based on the Smartkarma Smart Scores. With high scores in Value and Dividend at 4 each, the company showcases strong fundamentals and a commitment to shareholder returns. Additionally, its Momentum score of 5 indicates strong market performance and investor interest. Although Growth and Resilience scores are slightly lower at 3, Fresenius & KGaA’s diverse product offerings in dialysis, hospital care, and medical home services provide a stable foundation for future expansion.
Overall, Fresenius SE & Co KGaA’s Smartkarma Smart Scores paint a positive outlook. The company’s solid Value and Dividend scores, coupled with strong Momentum, suggest a promising trajectory for investors seeking stability and growth potential in the healthcare sector. With its broad range of healthcare products and services, Fresenius & KGaA appears well-positioned to navigate market challenges and capitalize on opportunities in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
